Celgene (CELG) Reports Data from Phase III Trial of VIDAZA(R) Shows Treatment Can Improve Patient Responses
Celgene International Sarl (NASDAQ: CELG) reports that an analysis presented today of a phase III international clinical trial (AZA-001) of higher-risk patients with myelodysplastic syndromes, demonstrated that continued treatment with VIDAZA (azacitidine) can improve patient responses.
In the study, 51% (91/179) of patients treated with VIDAZA responded with complete remission, partial remission or improvements in blood counts. The median number of cycles to first response was two; 87% of patients who responded achieved a first response by six cycles, and 91% of responders achieved a first response by nine cycles. For 52% of the responders, their first response was their best response; 48% had an increase in their response category after additional treatment cycles.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States.
In the study, 51% (91/179) of patients treated with VIDAZA responded with complete remission, partial remission or improvements in blood counts. The median number of cycles to first response was two; 87% of patients who responded achieved a first response by six cycles, and 91% of responders achieved a first response by nine cycles. For 52% of the responders, their first response was their best response; 48% had an increase in their response category after additional treatment cycles.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States.
You May Also Be Interested In
- Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference
- Sony (SNE) Said to Pay for 3-D Glasses for 'Men In Black 3' -Bloomberg (RLD)
- Hill International (HIL) Receives $16.1 Million Contract From LA County Metro Transportation Authority
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
